Cancer medicines
Venetoclax
Venetoclax
An oral leukemia-targeted medicine inhibiting BCL-2.
Sources checked · Introductory guide
On this page
How it works
It blocks the survival protein BCL-2 to promote cancer cell death.[3]
Where it is used
Used in CLL/SLL and selected AML. AML combinations include azacitidine, decitabine or low-dose cytarabine according to treatment suitability.[1]
Key safety points
Follow the escalation, hydration, preventive medicine and blood-test plan for tumor lysis prevention. Check interactions, including antifungals; do not increase or restart it yourself. Report low urine, confusion or severe vomiting immediately.[2]
Questions for your care team
- What is my tumor lysis prevention and urgent contact plan when starting or restarting?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Venetoclax (opens in a new tab)
- MedlinePlus · Venetoclax (opens in a new tab)
- NCI Drug Dictionary · Venetoclax (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.